TD Cowen analyst Michael Nedelcovych lowered the firm’s price target on Novo Nordisk (NVO) to $70 from $105 and keeps a Buy rating on the shares. The firm met with management who noted the current GLP-1 portfolio faces headwinds but guidance now brackets downside scenarios and the company is not interested in a race to the bottom on price but they are excited by the oral sema obesity opportunity which should benefit from a bolstered cash pay option.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- Novo Nordisk, BioMed X launch new collaboration in oral peptide drug delivery
- Hims & Hers Health Stock Falls While GoodRx Rallies on Deal with Novo Nordisk
- Novo Nordisk’s Strategic Focus on Obesity Market and Oral Semaglutide Drives Buy Rating
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories
- Bullish flow in Novo Nordisk with shares up 4.88%